Arena Pharmaceutical (ARNA) 1.56 $ARNA Arena

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Arena Pharmaceutical (ARNA) 1.56 $ARNA

Arena Pharmaceutics Announces Formation of Beacon Discovery
PR Newswire - Thu Sep 01, 3:30PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the formation of Beacon Discovery Inc. ("Beacon", an independent, privately-held drug discovery incubator.
ARNA: 1.56 (+0.01)

Actelion (ALIOF) Uptravi Approved for PAH in Switzerland
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 7:29AM CDT
Actelion (ALIOF) announced that Uptravi was granted approval by Swissmedic for treatment of patients with pulmonary arterial hypertension (PAH).
ANIP: 61.42 (+1.68), ANIK: 47.94 (+0.70), ARNA: 1.56 (+0.01)

Arena Pharmaceuticals Announces Appointment of Vincent Aurentz as Chief Business Officer
PR Newswire - Mon Aug 15, 6:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced that Vincent Aurentz will join its management team as Executive Vice President and Chief Business Officer, effective today. Mr. Aurentz will report to Amit Munshi, Arena's President and Chief Executive Officer.
ARNA: 1.56 (+0.01)

Arena's (ARNA) Q2 Loss Narrower, Revenues Increase Y/Y
Arpita Dutt - Zacks Investment Research - Tue Aug 09, 6:19AM CDT
Arena (ARNA) continues to work on the advancement of its proprietary pipeline candidates.
HSKA: 52.76 (-1.81), CBM: 43.17 (+0.34), ANIP: 61.42 (+1.68), ARNA: 1.56 (+0.01)

Arena Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update
PR Newswire - Mon Aug 08, 3:01PM CDT
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), today reported financial results for the second quarter ended June 30, 2016, and provided a corporate update.
ARNA: 1.56 (+0.01)

Biotech Stocks Technical Report -- Arena Pharma, BIND Therapeutics, Nektar Therapeutics, and Regeneron Pharma
PR Newswire - Wed Aug 03, 7:50AM CDT
Stock-Callers.com focus is on the Biotech arena which has had an impressive performance in the last few days. On Monday, August 01, 2016, stocks within the biotech space drove the NYSE Arca Biotechnology Index up by 2.4%. Today, we review Arena Pharmaceuticals Inc. (NASDAQ: ARNA), BIND Therapeutics Inc. (NASDAQ: BIND), Nektar Therapeutics (NASDAQ: NKTR), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Today's research reports on the aforementioned stocks are downloadable for free upon registration at:
BIND: 0.78 (-0.09), ARNA: 1.56 (+0.01), REGN: 393.40 (+0.85), NKTR: 18.11 (+0.26)

Arena Pharmaceuticals to Release Second Quarter 2016 Financial Results and Provide Corporate Update on Monday, August 8, 2016
PR Newswire - Mon Aug 01, 3:01PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that the Company will release its second quarter 2016 financial results and provide a corporate update on Monday, August 8, 2016, after the close of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community on Monday, August 8, 2016 at 4:30 p.m. ET to discuss the financial results and provide a corporate update.
ARNA: 1.56 (+0.01)

Arena (ARNA) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon Aug 01, 7:56AM CDT
Will an improvement in Belviq's performance help Arena (ARNA) deliver a surprise in Q2?
FATE: 2.45 (-0.15), ARNA: 1.56 (+0.01), EXEL: 11.35 (+0.20)

How These Biotech's Stocks are Performing? - Intrexon, Vertex Pharma, Arena Pharma, and Regeneron Pharma
PR Newswire - Thu Jun 23, 6:30AM CDT
The Biotechnology industry might still be in rough waters, but it continues to present great opportunities to investors. Stock-Callers.com assesses the recent performances of our featured companies for today: Intrexon Corp. (NYSE: XON), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Learn more about these stocks and receive your complimentary trade alerts at:
VRTX: 94.75 (+0.24), XON: 25.29 (+0.05), ARNA: 1.56 (+0.01), REGN: 393.40 (+0.85)

Arena Pharmaceuticals Announces USAN Approval of Nonproprietary Name "Etrasimod" for its Drug Candidate APD334
PR Newswire - Mon Jun 13, 6:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the United States Adopted Names (USAN) Council has approved the nonproprietary name etrasimod (pronounced Et-ras'-i-mod) for APD334, a selective oral, investigational, Sphingosine 1-Phosphate Subtype 1 (S1P1) receptor modulator with therapeutic potential in autoimmune diseases. Arena is currently studying etrasimod in a Phase 2 clinical trial for ulcerative colitis.
ARNA: 1.56 (+0.01)

Orexigen Stock Gains More than 50% on Markman Hearing
Arpita Dutt - Zacks Investment Research - Thu Jun 09, 7:58AM CDT
Orexigen's (OREX) shares shot up on a favorable Markman hearing in the Contrave patent infringement lawsuit.
OREX: 3.92 (-0.01), RTRX: 16.35 (+0.33), VVUS: 1.06 (unch), ARNA: 1.56 (+0.01)

Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:51AM CDT
As of late, it has definitely been a great time to be an investor in Arena Pharmaceuticals, Inc. (ARNA)
ARNA: 1.56 (+0.01)

Arena's (ARNA) Q1 Loss Narrower but Revenues Fall Short
Arpita Dutt - Zacks Investment Research - Tue May 10, 7:27AM CDT
Sales of Arena's (ARNA) obesity treatment, Belviq, remain lackluster.
HSKA: 52.76 (-1.81), CBM: 43.17 (+0.34), ANIP: 61.42 (+1.68), ARNA: 1.56 (+0.01)

Arena Pharmaceuticals reports 1Q loss
Automated Insights - Mon May 09, 4:07PM CDT
SAN DIEGO (AP) _ Arena Pharmaceuticals Inc. (ARNA) on Monday reported a loss of $21.5 million in its first quarter.
ARNA: 1.56 (+0.01)

Arena Pharmaceuticals Announces Appointment of Amit D. Munshi as President and Chief Executive Officer
PR Newswire - Mon May 09, 3:05PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it has appointed Amit D. Munshi as President, Chief Executive Officer and interim principal financial officer, effective May 11, 2016. Mr. Munshi will also join Arena's Board of Directors following Arena's 2016 annual stockholders' meeting, which is scheduled for June 13, 2016.
ARNA: 1.56 (+0.01)

Arena Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
PR Newswire - Mon May 09, 3:05PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported financial results for the first quarter ended March 31, 2016, and provided a corporate update.
ARNA: 1.56 (+0.01)

Drug Stocks Reporting Early Next Week: TEVA, ARNA & More
Arpita Dutt - Zacks Investment Research - Fri May 06, 8:43AM CDT
Drug companies like Teva (TEVA) and Arena (ARNA) will be reporting results early next week.
BDSI: 2.45 (+0.01), INO: 9.14 (-0.03), VVUS: 1.06 (unch), TEVA: 50.90 (+0.51), ARNA: 1.56 (+0.01), PBYI: 58.71 (-0.44)

Arena Pharmaceuticals to Host First Quarter 2016 Financial Results and Corporate Update Conference Call and Webcast on Monday, May 9
PR Newswire - Mon May 02, 3:05PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on Monday, May 9, 2016, to discuss first quarter 2016 financial results and provide a corporate update. Arena will issue a press release with its financial results after the NASDAQ Global Select Market closes that day.
ARNA: 1.56 (+0.01)

New Strong Sell Stocks for April 21st
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 6:46AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
AAOI: 17.14 (+0.29), ALIM: 1.55 (+0.02), ARES: 18.92 (+0.64), AXTA: 28.95 (+0.33), ARNA: 1.56 (+0.01)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 332

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 117

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 238

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Sivers Semiconductors: Strategy Behind 2027 AGM Plans

Updated Category News Views 46

Setting the Stage for a Crucial Year Ah, the dance of corporate governance—an arena where maneuvering is an art. Sivers Semiconductors AB, a name that's becoming synonymous with innovation in the photonics and wireless solutions sector, is prepping for its 2027 Annual General Meeting. Ahead of this pivotal event, they're forming a Nomination Committee to shape future...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 344

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Ericsson Completes Major Buyback in November Burst

Updated Category News Views 22

Ericsson's Aggressive Share Repurchase Strategy Ericsson's share buyback spree might not be the first rodeo for seasoned investors out there, but their recent grab between November 9th and 13th surely made a few heads turn. The telecom giant snatched up a neat pile of 500,000 of its own Class B shares, maintaining the steady tick of their ambitious buyback program. It's...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 216

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 160

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 15

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 292

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Willis Towers Watson's P/E Ratio Dynamics

Updated Category News Views 190

Current Stock Overview In today's market, Willis Towers Watson Inc. stock is priced at $325.59, reflecting a slight increase of 0.02%. Over the past month, the stock has risen by 5.11% and has shown a notable yearly increase of 17.73%. Such performance has led to optimism among long-term shareholders, although many are considering the price-to-earnings (P/E) ratio as a...

Continue Reading
Sterling Infrastructure to Engage Investors at Key Conferences

Updated Category News Views 79

Sterling Infrastructure to Engage Investors at Key Conferences Sterling Infrastructure, Inc. (NASDAQ: STRL) is making strides in connecting with investors by participating in several upcoming investor conferences. These events present a fantastic opportunity for the company's management to share insights and updates regarding their ongoing projects and strategic...

Continue Reading
Rivian's $5 Billion Factory Plans and Market Dynamics in EV

Updated Category News Views 224

Exciting Developments in the EV Industry The electric vehicle (EV) space has witnessed some thrilling changes recently. Major companies like Rivian, Tesla, and BYD are at the forefront of this industry evolution. This article will recap some standout events that have kept the tech world buzzing. Rivian's Ambitious Factory Plans Construction Begins on a $5 Billion Facility...

Continue Reading
Berry Global Group Secures $800 Million in Senior Notes

Updated Category News Views 273

Berry Global Group's Strategic $800 Million Notes Issuance Berry Global Group, Inc. (NYSE: BERY) has taken a significant step in bolstering its financial structure with the announcement of the issuance of $800 million in senior secured notes due in 2031. The notes, which carry an attractive interest rate of 7.250% per annum, reflect the company's ambition and strategic...

Continue Reading
AdaptHealth Corp. Welcomes Russell Schuster as CCO for Growth

Updated Category News Views 108

Russell Schuster Joins AdaptHealth as Chief Commercial Officer AdaptHealth Corp. (NASDAQ: AHCO), a prominent provider of patient-centered healthcare-at-home solutions, has made a significant addition to its leadership team by appointing Russell Schuster as Chief Commercial Officer. His role is effective immediately and brings a wealth of expertise aimed at enhancing the...

Continue Reading